Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPTNASDAQ:ETNBNASDAQ:HUMANASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$10.32-0.9%$8.79$2.99▼$10.87$1.57B1.81.57 million shs979,158 shsETNB89bio$10.41+8.2%$8.06$4.16▼$11.84$1.40B1.31.50 million shs3.93 million shsHUMAHumacyte$2.37-1.7%$1.91$1.15▼$9.79$367.63M23.87 million shs2.72 million shsJANXJanux Therapeutics$24.90-2.6%$27.02$22.48▼$71.71$1.47B2.96870,785 shs371,015 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-0.86%+2.28%+14.16%+41.76%+198.27%ETNB89bio+8.21%+1.56%+26.95%+22.90%+10.04%HUMAHumacyte-1.66%-8.49%+26.74%-22.04%-67.71%JANXJanux Therapeutics-2.58%-5.00%+10.08%-18.84%-41.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies2.6739 of 5 stars1.41.00.04.22.82.50.6ETNB89bio2.4953 of 5 stars3.53.00.00.02.80.80.6HUMAHumacyte2.3265 of 5 stars3.51.00.00.02.62.50.6JANXJanux Therapeutics2.3854 of 5 stars3.52.00.00.02.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.83Moderate Buy$9.83-4.72% DownsideETNB89bio 3.00Buy$26.43153.88% UpsideHUMAHumacyte 3.00Buy$11.71394.27% UpsideJANXJanux Therapeutics 3.09Buy$95.25282.53% UpsideCurrent Analyst Ratings BreakdownLatest HUMA, ADPT, ETNB, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/10/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.005/5/2025ADPTAdaptive BiotechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.005/2/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.004/30/2025ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$189.53M8.27N/AN/A$1.37 per share7.53ETNB89bioN/AN/AN/AN/A$5.75 per shareN/AHUMAHumacyte$517K711.09N/AN/A$0.13 per share18.23JANXJanux Therapeutics$9.34M157.83N/AN/A$7.46 per share3.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.96N/AN/AN/A-89.12%-64.65%-26.45%7/30/2025 (Estimated)ETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%8/4/2025 (Estimated)HUMAHumacyte-$110.78M-$0.69N/AN/AN/AN/A-942.81%-93.82%8/12/2025 (Estimated)JANXJanux Therapeutics-$58.29M-$1.36N/AN/AN/A-463.91%-10.47%-9.86%8/6/2025 (Estimated)Latest HUMA, ADPT, ETNB, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/1/2025Q1 2025ADPTAdaptive Biotechnologies-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.892.81ETNB89bio0.0911.6611.66HUMAHumacyteN/A1.101.10JANXJanux TherapeuticsN/A38.8038.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%ETNB89bioN/AHUMAHumacyte44.71%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%ETNB89bio2.60%HUMAHumacyte5.10%JANXJanux Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790151.92 million138.43 millionOptionableETNB89bio40145.98 million103.15 millionOptionableHUMAHumacyte150155.12 million111.76 millionOptionableJANXJanux Therapeutics3059.18 million37.05 millionOptionableHUMA, ADPT, ETNB, and JANX HeadlinesRecent News About These CompaniesCantor Fitzgerald Weighs in on JANX FY2026 EarningsJune 12 at 2:49 AM | americanbankingnews.comResearch Analysts Offer Predictions for JANX FY2026 EarningsJune 10, 2025 | marketbeat.comCalifornia State Teachers Retirement System Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)June 8, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Up 7.9% - Here's What HappenedJune 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Sees Significant Increase in Short InterestJune 5, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes $2.48 Million Position in Janux Therapeutics, Inc. (NASDAQ:JANX)June 3, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Wellington Management Group LLPJune 1, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 1, 2025 | marketbeat.comTwo Sigma Investments LP Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)May 31, 2025 | marketbeat.comNuveen Asset Management LLC Sells 39,145 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 31, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Squarepoint Ops LLCMay 30, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 4.2% - Should You Sell?May 29, 2025 | marketbeat.comMillennium Management LLC Invests $6.22 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)May 29, 2025 | marketbeat.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Has $22.99 Million Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)May 22, 2025 | marketbeat.comWoodline Partners LP Buys 251,924 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 22, 2025 | marketbeat.comRafferty Asset Management LLC Sells 13,522 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 22, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by AnalystsMay 22, 2025 | marketbeat.comDeutsche Bank AG Purchases 73,912 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)May 21, 2025 | marketbeat.comTroluce Capital Advisors LLC Buys New Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)May 20, 2025 | marketbeat.com50,000 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Purchased by Tang Capital Management LLCMay 20, 2025 | marketbeat.comPoint72 Asset Management L.P. Boosts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHUMA, ADPT, ETNB, and JANX Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$10.32 -0.09 (-0.86%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.32 +0.00 (+0.05%) As of 06/13/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.89bio NASDAQ:ETNB$10.41 +0.79 (+8.21%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.85 -0.56 (-5.42%) As of 06/13/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Humacyte NASDAQ:HUMA$2.37 -0.04 (-1.66%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Janux Therapeutics NASDAQ:JANX$24.90 -0.66 (-2.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$24.90 0.00 (0.00%) As of 06/13/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
